Relates to prescription drug formulary coverage for interchangeable biologics and biosimilars.
Relates to prescription drug formulary coverage for interchangeable biologics and biosimilars.
Requires managed care providers that provide coverage for prescription drugs to provide coverage for home delivery of any covered prescription by any non-mail-order retail pharmacy in the managed care provider network.
Provides for coverage for certain medically necessary prescription drugs in Medicaid managed care programs.
Relates to access to appropriate drugs at reasonable prices, formulary exceptions, standing prior authorizations and external appeals; to access to retail pharmacies, prescription synchronization, limits on patient drug costs, explanations of benefits and rebates; to prescription drug synchronization; to pharmacy benefit management; and to limits on copayments and drug substitutions.
Ensures that step therapy shall not apply to medically necessary prescription drugs in the dermatologic, hematology, ophthalmologic, rheumatic, gastrointestinal, neurology, and oncology therapeutic classes, including non-formulary drugs.
Ensures that step therapy shall not apply to medically necessary prescription drugs in the dermatologic, hematology, ophthalmologic, rheumatic, gastrointestinal, neurology, and oncology therapeutic classes, including non-formulary drugs.
Requires prescription drug containers be labeled with a description of the size, shape, color and imprint of the prescription drug it contains.
Requires prescription drug containers be labeled with a description of the size, shape, color and imprint of the prescription drug it contains.
Relates to utilization review program standards; requires use of evidence-based and peer reviewed clinical review criteria; relates to prescription drug formulary changes and pre-authorization for certain health care services.